Life without Panadol? GSK suspends its manufacture as they were going in loss

What happened: Panadol production has been suspended by GlaxoSmithKline Consumer Healthcare Pakistan. The company claims that producing the over-the-counter pharmaceutical on negative margins has become unsustainable. Why did it suspend: In a regulatory filing to the Pakistan Stock Exchange on October 19, the pharmaceutical company said it’s “forced to declare” force majeure (a condition in contracts that frees all parties from liability in an extraordinary event), with respect to the production of Panadol tablets, Panadol Extra tablets and children’s Panadol liquid range.  What you need to know: Topline Securities Deputy Head of Research Sunny Kumar told Dawn News that GlaxoSmithKline buys a “big chunk” of paracetamol, the raw material for Panadol products, from PSX-listed Citi Pharma Ltd and imports the rest from other nations, “The raw material imported by Citi Pharma to manufacture paracetamol has also become expensive,” he added, saying that it’s a ‘global phenomenon’